To the study design, obtained biopsy tissue specimens from sufferers, and

Towards the study style, obtained biopsy tissue specimens from patients, and participated inside the interpretation of results and drafting from the manuscript. JKR contributed to the study design and style, interpretation on the outcomes and drafting of the manuscript. SJJ and YSP contributed to the overview of pathologic findings, FISH analysis of MET, immunohistochemical evaluation of AXL, interpretation with the final results and drafting from the manuscript. SMC contributed to mutation evaluation working with mass spectrometric genetic evaluation (“Asan-Panel”), interpretation from the final results and drafting of your manuscript. WSK, JSL, SWK and DHL contributed towards the interpretation of outcomes and drafting in the manuscript. All authors study and authorized the final manuscript. Acknowledgments This study was supported by a grant from the Korean Health Technology R D Project, Ministry of Wellness Welfare (HI12C1146000013) along with a grant (2011-0529) from Asan Institute for Life Science, Seoul, Republic of Korea. Author information 1 Division of Pulmonary and Important Care Medicine, Asan Health-related Center, University of Ulsan College of Medicine, Seoul, Korea. 2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Seoul, Songpa-gu, Korea. 3Department of Pathology, Asan Health-related Center, College of Medicine, University of Ulsan, Seoul, Korea. Received: 26 July 2013 Accepted: 19 December 2013 Published: 27 December 2013 References 1.GDC-4379 Technical Information Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893917. two.G15 Data Sheet Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al: Screening for epidermal growth issue receptor mutations in lung cancer.PMID:28630660 N Engl J Med 2009, 361(10):95867. three. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):94757. 4. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is linked using a second mutation within the EGFR kinase domain. PLoS Med 2005, two(3):e73. 5. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):78692. six. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26. 7. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al: MET amplification results in gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039043. eight. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET amplification occurs with or with out T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104(52):209320937. 9. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al: Activation on the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.